First, we found that circIGF2BP3 was preferentially expressed in NSCLC cells compared with immune cells (CD45+, CD3+, CD4+ and CD8+ cells) isolated from PBMCs of NSCLC patients. This evidence concerns the gene PTPRC and non-small cell lung carcinoma.